These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6206831)

  • 1. Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism.
    Stern Y; Mayeux R; Côté L
    Arch Neurol; 1984 Oct; 41(10):1086-9. PubMed ID: 6206831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biochemical correlates of bradyphrenia in Parkinson's disease.
    Mayeux R; Stern Y; Sano M; Cote L; Williams JB
    Neurology; 1987 Jul; 37(7):1130-4. PubMed ID: 2439947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ; Logue M; Growdon JH
    Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease.
    Turkka JT; Juujärvi KK; Myllylä VV
    Eur Neurol; 1987; 26(1):29-34. PubMed ID: 3816883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.
    Mann JJ; Stanley M; Kaplan RD; Sweeney J; Neophytides A
    J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):905-10. PubMed ID: 6644314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between cisternal CSF and plasma concentrations of HVA, MHPG, 5-HIAA, DA, and NA.
    Degrell I; Nagy E
    Biol Psychiatry; 1990 May; 27(10):1179-82. PubMed ID: 1692743
    [No Abstract]   [Full Text] [Related]  

  • 7. Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid.
    Chase TN; Gordon EK; Ng LK
    J Neurochem; 1973 Sep; 21(3):581-7. PubMed ID: 4270247
    [No Abstract]   [Full Text] [Related]  

  • 8. Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.
    Herbert MK; Kuiperij H; Bloem BR; Verbeek MM
    J Neurol; 2013 Dec; 260(12):3129-33. PubMed ID: 24122060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments.
    Freed DM; Corkin S; Growdon JH; Nissen MJ
    Neuropsychologia; 1988; 26(6):895-902. PubMed ID: 2461537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites.
    Potter WZ; Scheinin M; Golden RN; Rudorfer MV; Cowdry RW; Calil HM; Ross RJ; Linnoila M
    Arch Gen Psychiatry; 1985 Dec; 42(12):1171-7. PubMed ID: 2416297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients.
    Linnoila M; Ninan PT; Scheinin M; Waters RN; Chang WH; Bartko J; van Kammen DP
    Arch Gen Psychiatry; 1983 Dec; 40(12):1290-4. PubMed ID: 6197036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF monoamine metabolites in mania.
    Swann AC; Secunda S; Davis JM; Robins E; Hanin I; Koslow SH; Maas JW
    Am J Psychiatry; 1983 Apr; 140(4):396-400. PubMed ID: 6188381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
    González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
    Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical course and CSF monoamine metabolism in neuroleptic malignant syndrome--a study of nine typical cases and five mild cases].
    Nishijima K; Ishiguro T
    Seishin Shinkeigaku Zasshi; 1989; 91(6):429-56. PubMed ID: 2479043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.
    Corona GL; Cucchi ML; Frattini P; Santagostino G; Schinelli S; Romani A; Pola A; Zerbi F; Savoldi F
    Eur Arch Psychiatry Neurol Sci; 1989; 239(2):79-86. PubMed ID: 2478368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered serotonin metabolism in depressed patients with parkinson's disease.
    Mayeux R; Stern Y; Cote L; Williams JB
    Neurology; 1984 May; 34(5):642-6. PubMed ID: 6200801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine activity correlates with psychometric deficits in Korsakoff's disease.
    Mair RG; McEntee WJ; Zatorre RJ
    Behav Brain Res; 1985 May; 15(3):247-54. PubMed ID: 2408635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memory impairment in Korsakoff's psychosis: a correlation with brain noradrenergic activity.
    McEntee WJ; Mair RG
    Science; 1978 Nov; 202(4370):905-7. PubMed ID: 715450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF monamine metabolites in movement disorders and normal aging.
    Stahl SM; Faull KF; Barchas JD; Berger PA
    Arch Neurol; 1985 Feb; 42(2):166-9. PubMed ID: 2579626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in human cerebrospinal fluid. Storage and measurement by reversed-phase high-performance liquid chromatography and coulometric detection using 3-methoxy-4-hydroxyphenyllactic acid as an internal standard.
    Javors MA; Bowden CL; Maas JW
    J Chromatogr; 1984 Dec; 336(2):259-69. PubMed ID: 6085084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.